Perimenopausal and postmenopausal hormone replacement therapy part 2. hormonal regimens and complementary and alternative therapies

Journal of Nurse-Midwifery

Volumn 41, Issue 3, 1996, Pages 195-210

  Lichtman, Ronnie ^a,b  

^a NewYork Presbyterian Hospital

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ALTERNATIVE MEDICINE; DRUG CONTRAINDICATION; ESTROGEN THERAPY; FEMALE; HUMAN; METHODOLOGY; MIDDLE AGED; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; REVIEW;

COMPLEMENTARY THERAPIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PRACTICE GUIDELINES; PREMENOPAUSE; PROGESTINS;

EID: 0030137704     PISSN: 00912182     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-2182(96)00020-1     Document Type: Article

References (109)

1. Lichtman R. Perimenopausal and postmenopausal hormone replacement therapy: part 1. an update of the literature on benefits and risks. J Nurse Midwifery 1996;41:3-28.
2. Levrant SG, Barnes RB. Pharmacology of estrogens. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven Press, 1994.
3. Lichtman R. Perimenopausal hormone replacement therapy: review of the literature. J Nurse Midwifery 1991;36:30-48.
4. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995;85:6-10.
5. Physicians' Desk Reference, 50th ed. Montvale (NJ): Medical Economics, 1996.
6. Baker VL. Alternatives to oral estrogen replacement: transdermal patches, percutaneous gels, vaginal creams and rings, implants, and other methods of delivery. Obstet Gynecol Clin North Am 1994;21:271-97.
7. Scharbo-Dehaan M. Management strategies for hormonal replacement therapy. Nurse Pract 1994; 19:47-57.
8. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility, 4th ed. Baltimore: Williams & Wilkins, 1989.
9. Silberstein SD, Merriam GR. Sex hormones and headache. J Pain Symptom Manage 1993;8:98-114.
10. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol 1990;75:77s-80s.
11. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA 1989:261:2095-100.
12. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
13. Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Delia Volpe C, Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs. oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 1991;62:l-8.
14. Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561-82.
15. Luf kin ES, Ory SJ. Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin Proc 1994;69:131-5.
16. Gordon SF. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol 1995;173:998-1004.
17. CHsham PR, Cedars MI, Greendale G, Fu YS, Gambone J, Judd HL. Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstet Gynecol 1992;79:196-201.
18. Norman-Taylor JQ, Crawford FE, Jenkins AW, Grudzinskas JG. Hormone replacement therapy by the transdermal administration of oestradiol and norethisterone. Maturitas 1994; 18:221-8.
19. Davis GF, Winter L Jr. Cumulative irritation study of placebo transdermal estrogen patches. Curr Ther Res 1987:42:712-9.
20. Utian WH. Transdermal estradiol overall safety profile. Am J Obstet Gynecol 1987;156:1335-8.
21. Frenkel Y, Kopernik G, Lazer S, Tugendreich D, Zmira N, Oettinger M, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994:20:31-6.
22. McCarthy T, Dramusic V, Ratnam S. Use of two types of estradiol-releasing skin patches for menopausal patients in a tropical climate. Am J Obstet Gynecol 1992; 166:2005-10.
23. O'Neill S, Kirkegard Y. An Australian experience of transdermal oestradiol patches in a subtropical climate. Aust NZ J Obstet Gynaecol 1993;33:327-9.
24. Gurwood AS, Gurwood I, Gubman DT. Brzezicki LJ. Idiosyncratic ocular symptoms associated with the estradiol transdermal estrogen replacement patch system. Optom Vis Sei 1995;72:29-33.
25. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993;16:185-202.
26. losif CS. Effects of protracted administration of estriol on the lower genito urinary tract in postmenopausal women. Arch Gynecol Obstet 1992:251:115-20.
27. Dupont A. Dupont P. Cusan L, Tremblay M, Rioux J, Cloutier D, et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991:13:297-311.
28. Kornafel KL, March CM. Estradiol gel in the treatment of menopausal symptoms: a placebo-controlled double-blind case study of efficacy and safety. South Med J 1992;85:270-3.
29. Sentrakul P, Chompootaweep S, Sintupak S, Tasanapradit P. Tunsaringkarn K, Dusitsin N. Adverse skin reactions to transdermal oestradiol in tropical climate. A comparative study of skin tolerance after using oestradiol patch and gel in Thai postmenopausal women. Maturitas 1991:13:151-4.
30. Tzingounis VA, Perdikaris AG. Lioutas G, Dimopoulos D. Subcutaneous hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993;49:64-6.
31. Hermens WA, Beider CW, Merkus JM, Hooymans PM, Verhoef J, Merkus FW. Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. Eur J Obstet Gynecol Reprod Biol 1992;43:65-70.
32. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The menopause study group. Am J Obstet Gynecol 1994;170:1213-23.
33. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75:59s-76s.
34. Smith RNJ, Holland EFN, Studd JWW. The symptomatology of progestogen intolerance. Maturitas 1994:18:87-91.
35. MacLennan AH, MacLennan A. Wenzel S, Chambers HM, Ecker K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J of Aust 1993:159:102-6.
36. Fraser D, Whitehead M, Schenkel L. Pryse-Davies J. Does lowdose, transdermal norethisterone acetate reliably cause endometrial transformation in postmenopausal oestrogen-users? Maturitas 1993:16:23-30.
37. Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 1989:161:948-51.
38. Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and endometrial effects of oestradiol and progesterone in postmenopausal women. Maturitas 1991:13:109-15.
39. Bolaji II, Talion DF, O'Dwyer, Fotrell PF. Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay. Gynecol Endocrinol 1993:7:101-10.
40. Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril 1994;61:790-2.
41. Marsh MS, Crook D, Whitcroft U, Worthington M, Whitehead MI, Stevenson JC. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994;83:19-23.
42. Cicinelli E, Savino F, Cagnazzo I, Scorcia P, Galantino P. Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. Gynecol Endocrinol 1992;6:247-51.
43. Cicinelli E, Cignarelli M, Resta L, Scorcia P, Petruzzi D. Santoro G. Effects of the repetitive administration of progesterone by nasal spray in postmenopausal women. Fertil Steril 1993;60:1020-4.
44. Cicinelli E, Petruzzi D, Scorcia P, Resta L. Effects of progesterone administered by nasal spray on the human postmenopausal endometrium. Maturitas 1993; 18:65-72.
45. Cicinelli E, Savino F, Cagnazzo I, Scorcia P. Comparative study of progesterone plasma levels after nasal spray and intramuscular administration of natural progesterone in menopausal women. Gynecol Obstet Invest 1993;35:172-4.
46. Andersson K, Mattsson LA, Rygo G, Stadberg E. Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-7.
47. Raudaskoski TH, Lahti El, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995:172:114-9.
48. Fraser IS. A review of the role of progestogens in hormonal replacement therapy: influence on bleeding patterns. Maturitas 1986;8:113-21.
49. Christiansen MS, Hagen C, Christiansen C, Transbol I. Doseresponse evaluation of cyclic estrogen/progestin in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873-9.
50. Rosenfeld J. Update on continuous estrogen-progestin replacement therapy. Am Fam Phys 1994;50:1519-23.
51. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162:153442.
52. Hirvonen E, Salmi T, Puolakka J, Heikkinen J, Granfors E, Hulkko S, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995;21:39-44.
53. Mishell DR Jr, Shoupe D, Moyer DL, Roy S, Page MA. Postmenopausal hormone replacement with a combination estrogen-progestin in regimen for five days per week. J Reprod Med 1991;36:3515.
54. Casper RF, Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 1993;168:1194-6.
55. Utian WH. Has "less than monthly progestin" come of age? Menopause Manage 1995;4:8.
56. Speroff L, Darney PD. A clinical guide for contraception. Baltimore: Williams & Wilkins, 1992.
57. Lip G, Beevers M, Churchill D, Beevers DG. Do clinicians prescribe HRT for hypertensive postmenopausal women? Br J Clin Pract 1995;49:61-4.
58. Pardo J, Kaplan B, Neri A, Blum M. Clinical and laboratory work-up prior to hormone replacement therapy in postmenopausal women. Clin Exp Obstet Gynecol 1992; 19:215-7.
59. Rozenberg S, Vandromme J, Kroll M, Praet JP, Peretz A, Ham H. Overview of the clinical usefulness of bone mineral measurement in the prevention of postmenopausal osteoporosis. Int J Fertil Menopausal Stud 1995;40:12-24.
60. Kaplan NM. The treatment of hypertension in women. Arch IntMed 1995; 155:563-7.
61. Creasman WT. Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer. Oncology 1992;6:23-6.
62. ACOG Committee on Gynecologic Practice. Estrogen replacement therapy and endometrial cancer. Int J Gynecol Obstet 1991;36:76.
63. Baker DP. Estrogen-replacement therapy in patients with previous endometrial carcinoma. Comp Ther 1990;16:28-35.
64. Creasman WT. Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol 1991;77:308-12.
65. Brzezinski A. Management of menopause in women with breast cancer. Israel J Med Sei 1995;31:163-8.
66. Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995:2:67-72.
67. Speroff L. Comment. Ob/Gyn Clin Alert 1995;12:41-2.
68. Sands R, Boshoff C, Jones A. Studd J. Current opinion: hormone replacement therapy after a diagnosis of breast cancer. Menopause 1995;2:73-80.
69. Belchetz PE. Hormonal treatment of postmenopausal women. N EngI J Med 1994;330:1062-71.
70. MacLennan AH. Running a menopause clinic. Baillieres Clin Endocrinol Metabol 1993;7:243-53.
71. Chambers JT, Chambers SK. Endometrial sampling: when? where? why? with what? Clin Obstet Gynecol 1992;35:28-39.
72. Carter J, Carson LF, Byers L, Moradi MM, Elg SA, Adcock LL et al. Transvaginal ultrasound in gynecologic oncology. Obstet Gynecol Surv 1991;46:687-96.
73. Nasri MN, Shepherd JH, Setchell ME, Lowe DG, Chard T. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991;98:470-5.
74. Botsis D, Kassanos D, Pyrgiotis E, Zourlas PA. Vaginal sonography of the endometrium in postmenopausal women. Clin Exp Obstet Gynecol 1992; 19:189-92.
75. Sheth S, Hamper UM, Kurman RJ. Thickened endometrium in the postmenopausal woman: sonographic-pathologic correlation. Radiology 1993;187:135-9.
76. Castelo-Branco C, Puerto B, Duran M, Gratacos E, Torne A, Fortuny A, Vanrell JA. Transvaginal sonography of the endometrium in postmenopausal women: monitoring the effect of hormone replacement therapy. Maturitas 1994;19:59-65.
77. Bakos O, Saith P, Heimer G. Transvaginal ultrasonography for identifying endometrial pathology in postmenopausal women. Maturitas 1994;20:181-9.
78. Shipley CF, Simmons CL, Nelson GH. Comparison of transvaginal sonography with endometrial biopsy in asymptomatic postmenopausal women. J Ultrasound Med 1993; 13:99-104.
79. Utian WH. Gallagher JC, Galsworthy TD, Lindsay R, Wingate JW. Advances in osteoporosis management. Menopause Manage 1995;4:12-19.40.
80. Vliet EL. An approach to perimenopausal migraine. Menopause Manage 1995;4:5-33.
81. Greenwood S. Testosterone supplements for women-a mixed blessing. Network News 1994; 19:3,8.
82. Faine MP. Dietary factors related to preservation of oral and skeletal bone mass in women. J Prosthet Dent 1995;73:65-72.
83. Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial) over 8 years. Maturitas 1995;21:71-6.
84. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
85. Shaver JL. Beyond hormonal therapies in menopause. Exp Gerontoi 1994;29:469-76.
86. Aloia JF, Vaswani A, Yeh JK, Ross PL, Plaster E, Dilmanian FA. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Int Med 1994;120:97-103.
87. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson K, Harris MM. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991;325:1189-95.
88. Heaney RP, Smith KP, Recker RR, Hinders SM. Meal effects on calcium absorption. Am J Clin Nutr 1989;49:372-6.
89. Dawson-Hughes B, Dallai GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;328:878-83.
90. Heaney RP. Bone mass, nutrition, and other lifestyle factors. Am J Med 1993;95:29s-33s.
91. Eaker E, Hahn RA. Women's health initiative [letter]. N Engl J Med 1994;330:70-1.
92. Kronenberg F. Giving hot flashes the cold shoulder-without drugs. Menopause Manage 1993;II:20-7.
93. Weed SS. Menopausal years. Woodstock (NY): Ashtree Publishing, 1992.
94. National Women's Health Network. Menopause: alternative therapies. Washington (DC): NWHN, 1995.
95. Baird DD, Umbach DM, Lansdell L, Hughes CL, Setchell KD, Weinberg CR, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metabol 1995;80:1685-90.
96. Herman C, Adlercreutz T, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, et al. Soybean phytoestrogen intake and cancer risk. J Nutr 1995;125:757S-70S.
97. Whitten PL, Lewis C, Russell E, Naftolin F. Potential adverse effects of phytoestrogens. J Nutr 1995;125:771s-6s.
98. Makkonen M, Simpanen AL, Saarikoski S, Uusitupa M, Penttila I, Silvasti M, Korhonen P. Endocrine and metabolic effects of guar gum in menopausal women. Gynecol Endocrinol 1993;7:135-41.
99. Pruitt LA, Jackson RD, Bartels RL, Lehnhard HJ. Weighttraining effects on bone mineral density in early postmenopausal women. J Bone Miner Res 1992:7:179-85.
100. Adarni S. Optimizing peak bone mass: what are the therapeutic possibilities? Osteoporosis Int 1994:4:27-30.
101. Caplan GA, Ward JA, Lord SR. The benefits of exercise in postmenopausal women. Aust J Public Health 1993;17:23-6.
102. Hammar M, Berg G, Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes? Acta Obstet Gynecol Scand 1990;69:409-12.
103. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992; 167:436-9.
104. Costlow J, Lopez MC, Taub M. Menopause: a self-care manual. Santa Fe (NM): Santa Fe Health Education Project, 1989.
105. Lobo RA. Treatment of the postmenopausal woman: where we are today. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven Press, 1994.
106. Harvard Women's Health Watch. Complementary medicine: commonly used herbal remedies. HWHW 1996;II:3.
107. Davis T. Homeopathy at menopause. Friend Indeed 1994;XI:l-2.
108. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sei 1990;592:52-86.
109. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995:332:1758-66.